Published in Clin Pharmacol Ther on May 22, 2013
Preemptive Pharmacogenomics Testing Among Geriatric Patients | NCT05091879
Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther (2013) 3.05
Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther (2014) 1.93
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet (2014) 1.49
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther (2015) 1.49
Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med (2013) 1.48
Pharmacogenetics: Using Genetic Information to Guide Drug Therapy. Am Fam Physician (2015) 1.39
Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet (2014) 1.19
Integration of genomics into the electronic health record: mapping terra incognita. Genet Med (2013) 0.98
Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med (2014) 0.97
Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians. J Biomed Inform (2015) 0.96
Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy (2014) 0.96
Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine. J Pers Med (2013) 0.91
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy (2014) 0.88
Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther (2016) 0.87
Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol (2015) 0.85
Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab Dispos (2014) 0.85
Genomic medicine, precision medicine, personalized medicine: what's in a name? Clin Pharmacol Ther (2013) 0.84
Clinician Perspectives on Using Pharmacogenomics in Clinical Practice. Per Med (2015) 0.84
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart (2015) 0.83
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet (2013) 0.83
Chasing Mendel: five questions for personalized medicine. J Physiol (2014) 0.83
Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole. Curr Fungal Infect Rep (2015) 0.83
Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics. Yearb Med Inform (2014) 0.83
Towards a molecular systems model of coronary artery disease. Curr Cardiol Rep (2014) 0.82
Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach. PLoS One (2015) 0.81
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clin Transl Sci (2016) 0.80
The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. Drug Metab Dispos (2015) 0.80
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol (2014) 0.80
A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI. Indian Heart J (2015) 0.80
Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Ther Clin Risk Manag (2015) 0.80
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol (2015) 0.79
Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm (2016) 0.79
Analysis of the CYP2C19 genetic polymorphism in Han and Uyghur patients with cardiovascular and cerebrovascular diseases in the Kashi area of Xinjiang. Med Sci Monit (2014) 0.79
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics (2016) 0.79
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther (2016) 0.79
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. Int J Environ Res Public Health (2017) 0.78
A conceptual model for translating omic data into clinical action. J Pathol Inform (2015) 0.78
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiol Res Pract (2017) 0.78
Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss-of function polymorphisms (*2/*3). Int J Cardiol (2016) 0.78
Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study. Br J Clin Pharmacol (2014) 0.77
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. Clin Pharmacokinet (2016) 0.77
Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy. Drug Metab Dispos (2016) 0.77
Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association. Circ Cardiovasc Genet (2016) 0.77
Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project. AMIA Annu Symp Proc (2015) 0.77
Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges. Clin Transl Sci (2016) 0.77
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J Am Heart Assoc (2015) 0.77
Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm (2016) 0.76
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada) (2014) 0.76
Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. Eur J Clin Pharmacol (2016) 0.76
Precision Medicine at the University of Alabama at Birmingham: Laying the foundational processes through implementation of Genotype-Guided Antiplatelet Therapy. Clin Pharmacol Ther (2017) 0.76
Pharmacogenetics in Jewish populations. Drug Metabol Drug Interact (2014) 0.75
Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data. PLoS One (2016) 0.75
PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics (2017) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
Prevalence of clinically actionable genotypes and medication exposure of older adults in the community. Pharmgenomics Pers Med (2017) 0.75
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenet Genomics (2017) 0.75
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. Ann Lab Med (2017) 0.75
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth Heart J (2016) 0.75
Evidence for extensive pleiotropy among pharmacogenes. Pharmacogenomics (2016) 0.75
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. Interv Cardiol Clin (2017) 0.75
Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS (2016) 0.75
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat Rev Drug Discov (2016) 0.75
Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel. Int J Mol Sci (2014) 0.75
Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. Am J Cardiol (2015) 0.75
Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation. PLoS One (2017) 0.75
Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients. Genet Test Mol Biomarkers (2016) 0.75
Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial. BMC Fam Pract (2016) 0.75
Cardiovascular Pharmacogenomics-Implications for Patients With CKD. Adv Chronic Kidney Dis (2016) 0.75
The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease. Sci Rep (2016) 0.75
Use of contemporary genetics in cardiovascular diagnosis. Circulation (2014) 0.75
Drug-gene interactions: inherent variability in drug maintenance dose requirements. P T (2014) 0.75
Implementation of inpatient models of pharmacogenetics programs. Am J Health Syst Pharm (2016) 0.75
Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci (2016) 0.75
EHR based Genetic Testing Knowledge Base (iGTKB) Development. BMC Med Inform Decis Mak (2015) 0.75
Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress. Future Cardiol (2015) 0.75
Clinical Trial Design in Juvenile Idiopathic Arthritis. Paediatr Drugs (2017) 0.75
Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data. Genet Med (2017) 0.75
Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs. Int J Clin Pharm (2017) 0.75
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther (2017) 0.75
A Knowledge-based System for Intelligent Support in Pharmacogenomics Evidence Assessment: Ontology-driven Evidence Representation and Retrieval. AMIA Jt Summits Transl Sci Proc (2017) 0.75
CYP2C19(⁎)2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls. Biomed Res Int (2017) 0.75
Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS One (2017) 0.75
Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmgenomics Pers Med (2017) 0.75
Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. Pharm Pract (Granada) (2017) 0.75
Factors affecting the obliteration rate of Intracranial Aneurysms treated with a single Pipeline Embolization Device. World Neurosurg (2017) 0.75
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. J Int Med Res (2016) 0.75
Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. Mol Genet Genomic Med (2017) 0.75
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther (2011) 10.95
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA (2011) 5.93
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med (2012) 4.37
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation (2010) 3.68
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 3.49
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost (2007) 3.38
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J (2009) 1.92
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J (2007) 1.61
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv (2011) 1.60
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol (2009) 1.57
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost (2010) 1.52
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics (2008) 1.52
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J (2010) 1.46
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics (2007) 1.43
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost (2010) 1.25
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics (2012) 1.25
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost (2009) 1.21
Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther (2012) 1.20
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA (2011) 1.19
Can we override clopidogrel resistance? Circulation (2009) 1.18
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost (2009) 1.12
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost (2012) 1.03
The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost (2013) 0.94
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost (2012) 0.91
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb Haemost (2012) 0.83
Genetic substudy of the PLATO trial. Lancet (2011) 0.81
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther (2011) 10.95
Factors associated with mortality in feedlot cattle: the Bruce County Beef Cattle Project. Can J Comp Med (1980) 7.74
Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther (2012) 6.92
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A (1998) 4.75
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
Factors associated with mortality and treatment costs in feedlot calves: the Bruce County Beef Project, years 1978, 1979, 1980. Can J Comp Med (1982) 4.34
Factors associated with morbidity and mortality in feedlot calves: the Bruce County beef project, year two. Can J Comp Med (1981) 4.17
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther (2012) 3.91
A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature (1999) 3.89
Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med (1995) 3.77
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther (2011) 3.50
Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med (1995) 3.25
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther (2012) 3.16
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol (2001) 2.86
The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med (2001) 2.74
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother (1996) 2.63
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther (2013) 2.38
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes (1997) 2.26
A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A (2000) 2.26
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Practice-based research: lessons from community pharmacist participants. Pharmacotherapy (2001) 2.23
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J Infect Dis (1996) 2.17
Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study. Diabetes Care (2000) 2.14
Isolation of vancomycin-resistant enterococci from animal feed in USA. Lancet (1999) 2.12
Distribution of Vibrio vulnificus in the Chesapeake Bay. Appl Environ Microbiol (1996) 2.10
Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A (1993) 2.07
Eu oxidation state in fluorozirconate-based glass ceramics. J Appl Phys (2009) 2.06
Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab (2012) 2.06
The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol (2000) 2.06
Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation (1996) 2.04
A research-based guideline for appropriate use of transdermal fentanyl to treat chronic pain. Oncol Nurs Forum (1998) 2.03
Cloning and sequence of a region encoding a surface polysaccharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol Microbiol (1996) 2.01
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 1.99
Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J Neurochem (2002) 1.96
Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun (1997) 1.96
The McGurk effect in infants. Percept Psychophys (1997) 1.96
Thermal conductivity spectroscopy technique to measure phonon mean free paths. Phys Rev Lett (2011) 1.94
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther (2013) 1.94
Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther (1999) 1.93
Accuracy of an electromagnetic tracking device: a study of the optimal range and metal interference. J Biomech (1996) 1.89
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.88
Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med (1995) 1.88
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther (2012) 1.88
A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res (1993) 1.85
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther (2014) 1.84
Drug-induced haemolysis masquerading as blackwater fever. Cent Afr J Med (1987) 1.82
Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia (2010) 1.76
Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J Infect Dis (1995) 1.75
Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation (1995) 1.75
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J (1986) 1.74
Relapsing invasive group B streptococcal infection in adults. Ann Intern Med (1995) 1.74
Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem (2001) 1.74
Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther (2014) 1.73
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther (2012) 1.72
Global parameter optimization for cardiac potassium channel gating models. Biophys J (1990) 1.72
Development and testing of a nonradioactive DNA oligonucleotide probe that is specific for Vibrio cholerae cholera toxin. J Clin Microbiol (1992) 1.71